[Skip to Content]
[Skip to Content Landing]

Sudden-Onset Monocular Blurry Vision in a Young Woman

Educational Objective
Based on this clinical scenario and the accompanying image, understand how to arrive at a correct diagnosis.
1 Credit CME

A 32-year-old woman who was admitted to the hospital for fever, flulike symptoms, and altered mental status developed sudden-onset blurry vision in her right eye. Her history was notable for phthisis in her left eye due to a left orbit clear cell sarcoma with metastatic disease, after surgical excision and radiation, with recent enrollment in a palliative immunotherapy research protocol. After completing 2 days of broad-spectrum intravenous antibiotics and antivirals for presumed septic meningitis, her laboratory and imaging results returned negative and she was transitioned to intravenous methylprednisolone (1 mg/kg). One day later, her mental status improved, and she reported central blurry vision in her right eye. On examination, her visual acuity was 20/40 in this eye, she had normal intraocular pressure, and there was no evidence of anterior chamber or vitreous cells. Dilated fundus examination revealed segmental areas of venous sheathing (Figure 1A) in the right eye and was not possible in the left eye owing to phthisis. An optical coherence tomography scan of the right eye revealed hyperreflective changes along the outer plexiform and outer nuclear layers, small intraretinal cysts, and disruption of the ellipsoid and especially the interdigitation zone (Figure 1B).

Please finish quiz first before checking answer.

You answered correctly!

Read the answer below and download your certificate.

You answered incorrectly.

Read the discussion below and retake the quiz.

Atezolizumab-associated retinopathy

B. Obtain information about the immunotherapy protocol initiated for her sarcoma

The clinical presentation of this patient is compatible with retinal toxicity associated with atezolizumab, an immune checkpoint inhibitor that targets the programmed death ligand 1.1 Checkpoint inhibitors are increasingly being used to treat metastatic malignancies, and their risk of inducing uveitis is well recognized among ophthalmologists.2 However, atezolizumab can also cause a specific form of retinopathy,1,3 which on optical coherence tomography and near infrared imaging demonstrates features similar to those observed with acute macular neuroretinopathy, with hyperreflective changes at the outer plexiform and outer nuclear layers that colocalize on near infrared to dark areas in addition to venulitis and small intraretinal cystic spaces, which are not typical features of acute macular neuroretinopathy.4

Survey Complete!

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author: Dean Eliott, MD, Massachusetts Eye and Ear, Harvard Medical School, 243 Charles St, Boston, MA, 02114 (dean_eliott@meei.harvard.edu).

Published Online: June 9, 2022. doi:10.1001/jamaophthalmol.2022.1327

Conflict of Interest Disclosures: Dr Eliott reported personal fees from Alcon, Allergan, Dutch Ophthalmic, Genentech, Aldeyra Therapeutics, and Pykus Therapeutics and grants from Neurotech and Unity Biotechnology outside the submitted work. No other disclosures were reported.

References
1.
Emens  LA , Davis  SL , Oliver  SCN ,  et al.  Association of cancer immunotherapy with acute macular neuroretinopathy and diffuse retinal venulitis.   JAMA Ophthalmol. 2019;137(1):96-100. doi:10.1001/jamaophthalmol.2018.5191PubMedGoogle ScholarCrossref
2.
Dalvin  LA , Shields  CL , Orloff  M , Sato  T , Shields  JA .  Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects.   Retina. 2018;38(6):1063-1078. doi:10.1097/IAE.0000000000002181PubMedGoogle ScholarCrossref
3.
Ramtohul  P , Freund  KB .  Clinical and morphological characteristics of anti-programmed death ligand 1-associated retinopathy: expanding the spectrum of acute macular neuroretinopathy.   Ophthalmol Retina. 2020;4(4):446-450. doi:10.1016/j.oret.2019.11.006PubMedGoogle ScholarCrossref
4.
Fawzi  AA , Pappuru  RR , Sarraf  D ,  et al.  Acute macular neuroretinopathy: long-term insights revealed by multimodal imaging.   Retina. 2012;32(8):1500-1513. doi:10.1097/IAE.0b013e318263d0c3PubMedGoogle ScholarCrossref
5.
Gass  JD .  Pathogenesis of disciform detachment of the neuroepithelium.   Am J Ophthalmol. 1967;63(3):Suppl:1-139.Google Scholar
6.
Kaye  R , Chandra  S , Sheth  J , Boon  CJF , Sivaprasad  S , Lotery  A .  Central serous chorioretinopathy: an update on risk factors, pathophysiology and imaging modalities.   Prog Retin Eye Res. 2020;79:100865. doi:10.1016/j.preteyeres.2020.100865PubMedGoogle ScholarCrossref
7.
Reichstein  D .  Current treatments and preventive strategies for radiation retinopathy.   Curr Opin Ophthalmol. 2015;26(3):157-166. doi:10.1097/ICU.0000000000000141PubMedGoogle ScholarCrossref
AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
  • 1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
  • 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
  • 1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
  • 1.00 CME points in the American Board of Surgery’s (ABS) Continuing Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close